At the latest AmCham Policy Forum, we discussed the European Commission's Pharmaceutical Strategy for Europe, designed to ensure patients have access to innovative and affordable medicines and to support the competitiveness, innovative capacity and sustainability of the industry.
According to Csaba Kontor, Health Attaché of the Permanent Representation of Hungary to the EU, the strategy has five pillars:
- Addressing unmet medical needs, such as in the areas of antimicrobial resistance, cancer, rare diseases, etc,
- Facilitating access through revised incentives, ip rights, revised legislation,
- Ensuring affordability by increasing pricing transparency, supporting competition after the expiriy of exclusivity,
- Supporting the competitiveness of the sector by fostering innovation, simplifying approval, supporting data transfer, high performance computing and AI as well as implementing clinical trials regulations,
- Building resiliency in the sector to protect supply chains and improve crisis preparedness.
Kontor says a globally competitive European pharmaceutical industry is needed and the commission is urging all stakeholders to participate in the creation and the execution of the strategy.
AmCham's Healthcare Working Group released Cooperation for a Sustainable and Value Based Healthcare 2021 recommendation package in May to establish a constructive cooperation with policymakers in order to advance healthcare reform and the health sector towards value-based, people-centered and sustainable solutions and services.